-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
Science
-
Research updates, April 22
-
Research updates, April 15
-
“It’s like torture”: The tilt table test could be risky for many people with Long COVID
-
Research updates, April 8
-
Lisa McCorkell reflects on five years of Long COVID research, and leaving PLRC
-
What we know about the U.S. bird flu outbreak and its chronic disease risk
Covid-19
Health
-
New Long Covid and ME apps aim to share information, build community
-
#MEAction launches campaign to educate healthcare providers about Myalgic Encephalomyelitis
-
Bird flu is spreading through U.S. farms. What are the risks to people?
-
‘People need help now’—Why NYC’s unique Long Covid programs aren’t enough
-
Hidden disability: The quiet struggle with Long Covid in Kenya
-
Want to enroll in a Long Covid clinical trial? This new project helps track them.
-
Missives from the dismissed: Still COVIDing without community
-
A timely book of poetry chronicles a mother — and her daughters’ — experience with Long COVID
-
An international emergency task force is urgently needed for Severe Long COVID and ME crisis cases
-
The history of ME deserves a late-night spotlight. That’s why we started the #JohnVsJonVsME campaign.